Edesa Biotech Revenue and Competitors
Estimated Revenue & Valuation
- Edesa Biotech's estimated annual revenue is currently $3.6M per year.
- Edesa Biotech's estimated revenue per employee is $155,000
Employee Data
- Edesa Biotech has 23 Employees.
- Edesa Biotech grew their employee count by 15% last year.
Edesa Biotech's People
| Name | Title | Email/Phone |
|---|
Edesa Biotech Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.7M | 9 | -72% | $39.4M | N/A |
#2 | $0.9M | 11 | -83% | $23.8M | N/A |
#3 | $87.6M | 565 | 6% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $7.8M | 50 | -68% | N/A | N/A |
#6 | $13.5M | 87 | 30% | N/A | N/A |
#7 | $17.8M | 115 | -6% | N/A | N/A |
#8 | $0.9M | 11 | -39% | N/A | N/A |
#9 | $13.6M | 88 | -20% | $86M | N/A |
#10 | $20M | 129 | -12% | N/A | N/A |
What Is Edesa Biotech?
Founded in 2015, Edesa Biotech brings innovative new treatments for dermatological and anorectal diseases. Late-stage prescription drugs developed by Edesa Biotech aim to help patients who experience limited treatment options. Edesa Biotech's focus on dermatology is led by an experienced team that have licensed global rights to clinical stage assets for dermatology and anorectal indications.
keywords:N/A
N/A
Total Funding
23
Number of Employees
$3.6M
Revenue (est)
15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Edesa Biotech News
TORONTO, ON / ACCESSWIRE / April 28, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on...
Several hedge funds and other institutional investors have recently bought and sold shares of EDSA. UBS Group AG grew its stake in Edesa Biotech...
Edesa Biotech is developing two product candidates aimed at improving the quality of life of ACD patients and also saving the lives of thousands...
Other Companies in Markham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 23 | -38% | N/A |
#2 | $4.7M | 25 | -7% | N/A |
#3 | $2.5M | 25 | N/A | N/A |
#4 | $3.7M | 25 | 0% | N/A |
#5 | $2.5M | 26 | 0% | N/A |